Elizabeth Ahern
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Bone health and treatments
- CAR-T cell therapy research
- Physiology top 10%
- Adenosine and Purinergic Signaling
Papers in
- Oncology 21
- Cancer Immunotherapy and Biomarkers 10
- Colorectal Cancer Treatments and Studies 5
-
- Melanoma and MAPK Pathways 3
- Co-authors
- Mark J. Smyth (8 shared papers)William C. Dougall (7 shared papers)Michele W.L. Teng (6 shared papers)Heidi Harjunpää (3 shared papers)Stacey Allen (3 shared papers)Brett Hughes (8 shared papers)Deborah S. Barkauskas (2 shared papers)David Wyld (8 shared papers)
- Journals
- Journal of Clinical Oncology (5 papers)Seminars in Oncology (3 papers)BMJ Open (3 papers)OncoImmunology (3 papers)Molecular Cancer Therapeutics (2 papers)
- Partner nations
- AustraliaUnited StatesFrance
In The Last Decade
Elizabeth Ahern
35 papers receiving 603 citations
Peers
Comparison fields: 5 of 71
- Oncology 330
- Physiology 42
- Immunology 169
- Cancer Research 54
- Pulmonary and Respiratory Medicine 90
Countries citing papers authored by Elizabeth Ahern
This map shows the geographic impact of Elizabeth Ahern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Ahern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Ahern more than expected).
Fields of papers citing papers by Elizabeth Ahern
This network shows the impact of papers produced by Elizabeth Ahern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Ahern. The network helps show where Elizabeth Ahern may publish in the future.
Co-authors
The 25 scholars most cited alongside Elizabeth Ahern, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 78 | |
| 2 | 2018 | 77 | |
| 3 | 2017 | 70 | |
| 4 | 2018 | 70 | |
| 5 | 2018 | 54 | |
| 6 | 2021 | 44 | |
| 7 | 2018 | 39 | |
| 8 | 2019 | 22 | |
| 9 | 2020 | 21 | |
| 10 | 2022 | 15 | |
| 11 | 2021 | 13 | |
| 12 | 2020 | 12 | |
| 13 | 2024 | 11 | |
| 14 | 2019 | 9 | |
| 15 | 2020 | 8 | |
| 16 | 2020 | 7 | |
| 17 | 2021 | 7 | |
| 18 | 2024 | 6 | |
| 19 | 2024 | 5 | |
| 20 | 2024 | 5 |
About Elizabeth Ahern
Elizabeth Ahern is a scholar working on Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 40 papers that have together received 607 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (10 papers), Immunotherapy and Immune Responses (6 papers), Colorectal Cancer Treatments and Studies (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Lung Cancer Treatments and Mutations (4 papers), Melanoma and MAPK Pathways (3 papers), Ethics in Clinical Research (3 papers) and Glioma Diagnosis and Treatment (3 papers). The work is most often cited by research in Oncology (330 citations), Physiology (42 citations), Immunology (169 citations), Cancer Research (54 citations) and Pulmonary and Respiratory Medicine (90 citations). Elizabeth Ahern has collaborated with scholars based in Australia, United States and France. Frequent co-authors include Mark J. Smyth, William C. Dougall, Michele W.L. Teng, Heidi Harjunpää, Stacey Allen, Brett Hughes, Deborah S. Barkauskas, David Wyld, Jake S. O’Donnell and Kazuyoshi Takeda. Their work appears in journals such as Journal of Clinical Oncology, Seminars in Oncology, BMJ Open, OncoImmunology and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.